Alluvi, formerly BI 4744, presents a significant development in obesity therapy. This dual agonist targeting both GLP-1 and GIP receptors demonstrates remarkable effectiveness in patient studies, potentially https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/